Behavioural Intervention
HPV Education Interventions for Health Personnel Attitudes
This trial will compare two interventions to see which is more effective at reducing HPV vaccine hesitancy and increasing uptake and completion among people living in the El Paso U.S.-Mexico Border Region.
Popular Filters
Trials for HPV Patients
Cancer Vaccine
HPV Vaccine for HIV/AIDS
This trial will study the nonavalent HPV vaccine in adults with HIV to see if it produces a similar antibody response to the vaccine as people without HIV, and to observe short-term clinical outcomes of HPV infections.
CAR T-cell Therapy
E7 TCR T Cell Therapy for HPV-Related Cancers
This trial is testing a new therapy for HPV-associated cancers. Researchers will take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the HPV protein called E7. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer.
Trials for OPC Patients
CAR T-cell Therapy
E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer
This trial tests a new treatment using modified immune cells to fight cancers caused by HPV. It targets patients with specific types of cancer linked to HPV who have a certain genetic marker. The treatment works by reprogramming the patient's immune cells to attack the cancer cells.
Platinum-based Chemotherapy
Reduced Radiation + Chemotherapy for Oral Squamous Cell Carcinoma
This trial is comparing a less intense radiation therapy with 2 cycles of standard chemotherapy to the current standard chemoradiation for people with HPV positive and hypoxia negative T1-2, N1-2c oropharyngeal squamous cell carcinoma.
Radiation
Reduced-Intensity Radiation Therapy for Oropharyngeal Cancer
This trial is for patients with HPV-related oropharynx cancer. It tests a new radiation therapy that uses a lower dose over a shorter period. The goal is to reduce side effects while still effectively treating the cancer. The treatment of oropharyngeal cancer has shifted from surgery to radiotherapy, and the discovery of HPV's role has led to efforts to minimize treatment toxicity.
Cancer Vaccine
PDS0101 Vaccine + Pembrolizumab for Oropharyngeal Cancer
This trial is studying PDS0101, a vaccine made from specific peptides, either alone or in combination with pembrolizumab, to see how well it works in treating patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes.
Trials for P16 Positive Patients
Radiation
Reduced-Intensity Radiation Therapy for Oropharyngeal Cancer
This trial is for patients with HPV-related oropharynx cancer. It tests a new radiation therapy that uses a lower dose over a shorter period. The goal is to reduce side effects while still effectively treating the cancer. The treatment of oropharyngeal cancer has shifted from surgery to radiotherapy, and the discovery of HPV's role has led to efforts to minimize treatment toxicity.
Radiation Therapy
SABR Boost + Short-course Radiation for Oropharyngeal Cancer
This trial is testing whether a shorter, more intense course of radiation therapy is as effective as the standard 7-week course for treating oropharynx cancer associated with the human papillomavirus.
Phase 3 Trials
Radiation
Reduced-Intensity Radiation Therapy for Oropharyngeal Cancer
This trial is for patients with HPV-related oropharynx cancer. It tests a new radiation therapy that uses a lower dose over a shorter period. The goal is to reduce side effects while still effectively treating the cancer. The treatment of oropharyngeal cancer has shifted from surgery to radiotherapy, and the discovery of HPV's role has led to efforts to minimize treatment toxicity.
Trials With No Placebo
CAR T-cell Therapy
E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer
This trial tests a new treatment using modified immune cells to fight cancers caused by HPV. It targets patients with specific types of cancer linked to HPV who have a certain genetic marker. The treatment works by reprogramming the patient's immune cells to attack the cancer cells.
Cancer Vaccine
HPV Vaccine for HIV/AIDS
This trial will study the nonavalent HPV vaccine in adults with HIV to see if it produces a similar antibody response to the vaccine as people without HIV, and to observe short-term clinical outcomes of HPV infections.
Platinum-based Chemotherapy
Reduced Radiation + Chemotherapy for Oral Squamous Cell Carcinoma
This trial is comparing a less intense radiation therapy with 2 cycles of standard chemotherapy to the current standard chemoradiation for people with HPV positive and hypoxia negative T1-2, N1-2c oropharyngeal squamous cell carcinoma.
Radiation
Reduced-Intensity Radiation Therapy for Oropharyngeal Cancer
This trial is for patients with HPV-related oropharynx cancer. It tests a new radiation therapy that uses a lower dose over a shorter period. The goal is to reduce side effects while still effectively treating the cancer. The treatment of oropharyngeal cancer has shifted from surgery to radiotherapy, and the discovery of HPV's role has led to efforts to minimize treatment toxicity.
View More Related Trials
Frequently Asked Questions
Introduction to hpv
What are the top hospitals conducting hpv research?
When it comes to clinical trials focused on HPV, several hospitals are leading the charge in advancing our understanding and treatment of this prevalent virus. The National Institutes of Health Clinical Center in Bethesda stands out as a notable institution with four active HPV trials currently underway. With five total trials conducted since their first recorded trial in 2017, they have been at the forefront of research into this virus that affects millions worldwide.
In Rochester, Minnesota, the renowned Mayo Clinic is actively involved in three ongoing HPV trials. While they do not have any previous recorded HPV trials to their name, their dedication to exploring new avenues for treating and preventing this virus is commendable.
Meanwhile, Acevedo Clinical Research Associates (Site 0001) in Miami has made significant contributions to HPV research by conducting two active trials and having completed two additional studies since embarking on their first trial in 2020. Their commitment to finding innovative solutions for those affected by HPV highlights the importance placed on addressing this pressing health concern.
In Chicago's Anal Dysplasia Clinic MidWest, researchers are actively engaged in two ongoing clinical trials focusing on HPV. Although they do not possess any prior recorded HPV studies, their current efforts demonstrate a dedication towards furthering knowledge about this virus and its potential impact on individuals' health.
Lastly from New york City where Laser Surgery Care contributes significantly through participating in two current HPv testing while leaving no trail previously; laser surgery care prioritizes providing exceptional healthcare services imbued with advanced technology aimed at aiding patients battling Hpv infections. Through these collaborative efforts across various locations nationwide,it becomes evident that medical professionals are dedicating themselves tirelessly to develop novel approaches againstHPV.Moreover,hospitals embracing these initiatives signify a beaconof hopefor individuals grapplingwiththeimplicationsandintricaciesofHPVinfections.Through such ambitious ventures,better treatmentsandpreventive measuresarebeing pursued,resultingin abrighterfutureforallthoseaffectedbythisglobal healthconcern.
Which are the best cities for hpv clinical trials?
When it comes to HPV clinical trials, several cities have emerged as leaders in research and development. New york leads the pack with 8 active trials focused on studying treatments like the 9vHPV Vaccine and laboratory biomarker analysis. Miami closely follows with 6 ongoing studies examining interventions such as the 9vHPV Vaccine and Cisplatin. Bethesda and Houston tie for third place, each hosting 5 active trials exploring various treatments including PRGN-2012 and Cemiplimab. Lastly, Tucson boasts 4 active trials investigating options like Recombinant Human Papillomavirus Nonavalent Vaccine. These cities offer individuals participating in HPV clinical trials access to cutting-edge research that contributes to advancements in care for this prevalent virus.
Which are the top treatments for hpv being explored in clinical trials?
In the realm of HPV research, one treatment stands out as a frontrunner in clinical trials. The 9vHPV vaccine has caught the attention of researchers with its potential to combat this prevalent virus. Currently, there are two active trials dedicated to exploring its effectiveness. Since its introduction in 2020, it has been part of three all-time HPV trials, showcasing promising advancements in our fight against this pervasive infection. As scientists delve deeper into understanding and treating HPV, the 9vHPV vaccine holds great promise for improving outcomes and preventing related diseases worldwide
What are the most recent clinical trials for hpv?
Exciting developments are occurring in the field of HPV research, with recent clinical trials exploring promising avenues for treatment and prevention. One such trial investigates Arm 1, a Phase 2 study aimed at evaluating new therapeutic approaches to combat HPV infections. Additionally, Nitric Oxide Releasing Solution 2X is being examined in a Phase 2 trial as a potential intervention against HPV. Another trial focuses on Dose Escalation in its Phase 1 stage, assessing the safety and efficacy of various dosage levels for treating HPV-related conditions. Meanwhile, an advanced combined Phase 2/Phase 3 study is underway to assess the effectiveness of an innovative HPV vaccine. Finally, E7 TCR-T cells are being investigated in a Phase 2 trial as another possible avenue for combating HPV infection. These ongoing trials offer hope for improved outcomes among individuals affected by this prevalent virus
What hpv clinical trials were recently completed?
Recently, several clinical trials focused on Human Papillomavirus (HPV) have reached completion, bringing new insights and potential advancements to the field. These trials represent significant efforts in understanding and combating HPV-related diseases. Notably, a trial sponsored by the National Cancer Institute successfully concluded in September 2021. While specific details about this particular trial are not provided here, it is an important contribution to the ongoing battle against HPV and its associated conditions. The research community's commitment to finding innovative solutions for preventing and treating HPV continues to drive progress in this area of healthcare.